Glymphatic system dysfunction in neurodegenerative diseases
Research output: Contribution to journal › Review › Research › peer-review
Standard
Glymphatic system dysfunction in neurodegenerative diseases. / Beschorner, Natalie; Nedergaard, Maiken.
In: Current Opinion in Neurology, Vol. 37, No. 2, 2024, p. 182-188.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glymphatic system dysfunction in neurodegenerative diseases
AU - Beschorner, Natalie
AU - Nedergaard, Maiken
N1 - Publisher Copyright: Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2024
Y1 - 2024
N2 - Purpose of review Purpose of this review is to update the ongoing work in the field of glymphatic and neurodegenerative research and to highlight focus areas that are particularly promising. Recent findings Multiple reports have over the past decade documented that glymphatic fluid transport is broadly suppressed in neurodegenerative diseases. Most studies have focused on Alzheimer’s disease using a variety of preclinical disease models, whereas the clinical work is based on various neuroimaging approaches. It has consistently been reported that brain fluid transport is impaired in patients suffering from Alzheimer’s disease compared with age-matched control subjects. Summary An open question in the field is to define the mechanistic underpinning of why glymphatic function is suppressed. Other questions include the opportunities for using glymphatic imaging for diagnostic purposes and in treatment intended to prevent or slow Alzheimer disease progression.
AB - Purpose of review Purpose of this review is to update the ongoing work in the field of glymphatic and neurodegenerative research and to highlight focus areas that are particularly promising. Recent findings Multiple reports have over the past decade documented that glymphatic fluid transport is broadly suppressed in neurodegenerative diseases. Most studies have focused on Alzheimer’s disease using a variety of preclinical disease models, whereas the clinical work is based on various neuroimaging approaches. It has consistently been reported that brain fluid transport is impaired in patients suffering from Alzheimer’s disease compared with age-matched control subjects. Summary An open question in the field is to define the mechanistic underpinning of why glymphatic function is suppressed. Other questions include the opportunities for using glymphatic imaging for diagnostic purposes and in treatment intended to prevent or slow Alzheimer disease progression.
KW - Alzheimer’s disease
KW - brain clearance
KW - cerebral amyloid angiopathy
KW - glymphatic system
KW - protein aggregation
U2 - 10.1097/WCO.0000000000001252
DO - 10.1097/WCO.0000000000001252
M3 - Review
C2 - 38345416
AN - SCOPUS:85187207796
VL - 37
SP - 182
EP - 188
JO - Current Opinion in Neurology
JF - Current Opinion in Neurology
SN - 1350-7540
IS - 2
ER -
ID: 385901487